...
Loading...4 min read

Target Identification in Prostate Cancer

Limited therapeutic efficacy and drug resistance in advanced-stage prostate cancer contributes to poor outcomes, highlighting the need for targeted therapies with alternative mechanisms of action. Here, we leveraged human-centric AI to accelerate target identification for prostrate adenocarcinoma.

Elizabeth Bolitho

November 27, 2023

Loading...4 min read

Save Time, Reduce Bias, Make Better Decisions

With almost half a million papers on obesity in PubMed, and 2 papers added per minute, identifying promising therapeutic targets is time-consuming, subject to bias and is not always comprehensive. Causaly extracts insights rather than papers, uncovering over 5,000 targets for obesity in seconds.

Elizabeth Bolitho

November 15, 2023

Loading...4 min read

Streamlining Target Identification: A Diabetes Use Case

The rising prevalence of T1D demands new treatments. The identification and understanding of targets for T1D for developing effective drugs and alleviating patient burdens. AI can streamline this process by dramatically reducing reading time, minimizing bias and uncovering hidden target-disease insights, enabling the exploration of more promising avenues.

Elizabeth Bolitho

November 13, 2023

Filter by:

Oncology

Elizabeth Bolitho • November 27, 2023

Target Identification in Prostate Cancer

Limited therapeutic efficacy and drug resistance in advanced-stage prostate cancer contributes to poor outcomes, highlighting the need for targeted therapies with alternative mechanisms of action. Here, we leveraged human-centric AI to accelerate target identification for prostrate adenocarcinoma.

Elizabeth Bolitho • October 30, 2023

Targets for Breast Cancer Studied in Animal Models

Early-stage triple-negative breast cancer (TNBC) primarily relies on surgery and chemotherapy, yet its response is often suboptimal compared to other breast cancer subtypes. The development of targeted therapies is crucial to improve prognosis, enhance treatment efficacy and mitigate drug resistance. Identifying novel therapeutic pathways holds the potential to transform TNBC treatment.

Elizabeth Bolitho • October 9, 2023

Target Identification and Prioritization: Blood Cancer

Despite available treatments for blood cancer, achieving sufficient dosage at the tumor site for therapeutic efficacy is difficult, underscoring the crucial need for improved targeted therapies. Here we used Causaly to identify and prioritize potential targets for Diffuse Large B Cell Lymphoma (DLBCL) – the most prevalent Non-Hodgkin Lymphoma.     

Elizabeth Bolitho • October 2, 2023

The Promise of Immuno-oncology in Bladder Cancer

Bladder cancer treatments are hampered by high recurrence, requiring multiple therapeutic interventions which are highly invasive and cause side effects, underscoring the need for innovative treatments. In the pursuit of advancing bladder cancer treatment, immuno-oncology shows promise. This blog delves into the importance of identifying antigens in the development of targeted cancer therapies.  

Elizabeth Bolitho • September 18, 2023

Genetic Alterations Affecting Ubiquitination in Multiple Myeloma

Ubiquitination plays a key role in the pathophysiology of multiple myeloma, highlighting its promise as a therapeutic target for this plasma cell malignancy. In this blog, we used Causaly to explore genetic alterations affecting by ubiquitination in multiple myeloma.

Elizabeth Bolitho • September 4, 2023

Targeting GOF Mutations in Leukemia: FLT3 and NOTCH1

Understanding GOF mutations is crucial for developing targeted therapies which inhibit the activity of aberrant proteins. Here, we explored FLT3 and NOTCH1 as GOF mutations associated with leukemia disease progression.

Elizabeth Bolitho • August 1, 2023

MicroRNAs as Targets for Lung Cancer

miRNA therapeutics face numerous challenges including targeted delivery, specificity, stability, immune response, and toxicity. Overcoming these challenges is paramount for success.

Elizabeth Bolitho • July 27, 2023

Identifying Targets for Oral Cancer

Head and neck cancers account for nearly 4% of all cancers in the US. The most common type is oral cancer, estimated to cause over 170,000 global deaths in 2020 alone. These statistics highlight the urgent need for more research and better treatments.

Elizabeth Bolitho • July 12, 2023

Identifying Targets in Gastrointestinal Stromal Tumors

Gastrointestinal (GI) stromal tumors are a rare form of soft tissue sarcoma of the digestive system, primarily affecting the stomach and small intestine. In the US, approximately 6000 new cases of GI stromal tumors are diagnosed each year. Despite their rarity, these tumors are the most prevalent mesenchymal tumors of the GI tract.